Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 87,490 Shares

by · The Cerbat Gem

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ra Capital Management, L.P. sold 87,490 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30. Following the sale, the insider directly owned 413,001 shares of the company’s stock, valued at $276,710.67. This represents a 17.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

  • On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64.
  • On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Stock Down 4.3%

HOWL traded down $0.03 on Tuesday, reaching $0.63. 500,207 shares of the company traded hands, compared to its average volume of 436,209. The company has a market cap of $30.71 million, a P/E ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a one year low of $0.53 and a one year high of $2.38. The firm has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.84.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.75.

View Our Latest Stock Analysis on HOWL

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in HOWL. Jane Street Group LLC bought a new stake in Werewolf Therapeutics during the second quarter valued at about $409,000. Renaissance Technologies LLC raised its holdings in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares in the last quarter. Citadel Advisors LLC bought a new position in Werewolf Therapeutics in the third quarter worth about $304,000. Vanguard Group Inc. lifted its position in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at about $113,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.

Read More